Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track KPRX with free AI briefings, catalyst countdowns, and dilution alerts.

KPRX · KIORA PHARMACEUTICALS INC

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$16.8M Cash on Hand
20mo Cash Runway
Follow KPRX by email Get an email when KPRX reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about KPRX, unsubscribe in one click. Privacy

📣 What KPRX Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
100 μg KIO-301 Retinitis Pigmentosa Phase 2 · NCT06628947 Recruiting
50 μg KIO-301 Retinitis Pigmentosa Phase 2 · NCT06628947 Recruiting
KIO-101 Dry Eye Disease Phase 2 · NCT05629364 Terminated
KIO-104 Macular Edema Phase 2 · NCT06825702 Recruiting
KIO-201, a Crosslinked Thiolated Carboxymethyl… Persistent Corneal Epithelial Defect Phase 2 · NCT05436288 Completed
KIO-301 Retinitis Pigmentosa Phase 1/2 · NCT05282953 Completed

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

KPRX holds $16.8M in cash and short-term investments (as of Jun 30, 2026) and burns about $2.5M/quarter from operations, an estimated runway of 20 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 40 · Elevated

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when KPRX files for a raise →

👥 Who Owns KPRX

Insiders 2.9% Other 5%+ holders 27.1% Institutions (26 holders) 36.8% Public and other holders 33.2%
HolderTypeShares% of sharesAs of
Nantahala Capital Management, LLC Institution (13G, 5%+) 491,889 11.12% 2026-06-30
ADAR1 Capital Management GP, LLC 5%+ holder (13G) 475,378 10.74% 2026-06-30
Rosalind Advisors, Inc. 5%+ holder (13G) 464,676 10.50% 2025-12-31
Perceptive Advisors LLC Institution (13G, 5%+) 442,387 10.00% 2026-04-06
Baselake Partners, LP 5%+ holder (13G) 257,500 5.82% 2026-09-10
Brian M. Strem
President and CEO, Director · +96,609 options
Insider 58,823 1.33% 2026-07-01
Eric Joseph Daniels
Chief Development Officer · +43,320 options
Insider 31,741 0.72% 2026-04-01
Melissa Tosca
CFO · +43,849 options
Insider 26,064 0.59% 2026-07-01
Praveen Tyle
Director · +70,000 options
Insider 5,014 0.11% 2024-08-19
Aron Shapiro
Director · +46,778 options
Insider 3,000 0.07% 2024-09-10
Carmine N. Stengone
Director · +46,778 options
Insider 1,250 0.03% 2024-09-11
Lisa Walters-Hoffert
Director · +46,778 options
Insider 1,250 0.03% 2024-08-19

Share count 4,424,387 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full KPRX picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for KPRX and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.